In-Vitro Diagnostics (IVD) Market to Record CAGR of 6.1% Over 2025-2032; Growing Cases of Chronic Diseases to Fuel Product Demand

The in-vitro diagnostics (IVD) market size was valued at USD 73.99 billion in 2024 and is predicted to reach USD 77.73 billion in 2025. The market is anticipated to touch USD 117.60 billion by 2032, recording a CAGR of 6.1% over 2025-2032.

Fortune Business Insights™ presents this information in its latest report titled “In-vitro Diagnostics (IVD) Market Size, Share & Industry Analysis, By Product Type (Instruments and Reagents & Consumables), By Technique (Immunodiagnostics [Enzyme Linked Immunosorbent Assay, Fluorescence immunoassay (FIA), Rapid test, and Others], Clinical Chemistry [Electrolyte Panel, Basic and Comprehensive Metabolic Panels, Liver Tests, Renal Tests, Lipid Panel, and Others], Molecular Diagnostics [Polymerase Chain Reaction (PCR), In Situ Hybridization, DNA Sequencing & Next-Generation Sequencing, and Others], Hematology, and Others), By Sample (Blood, Urine, Saliva, Tissue, and Others), By Setting (Laboratories and Point-of-Care), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Allergy, Autoimmunity, Prenatal Screening, and Others), By End-user (Clinical Laboratories, Hospitals, Physician’s Offices, and Others), and Regional Forecast, 2025-2032”.

In-vitro diagnostics (IVD) refers to medical instruments that are used to diagnose a wide range of chronic diseases, ranging from cardiovascular ailments to diabetes and cancer. These devices use biological samples, such as urine, blood, and tissues, to help medical professionals detect these diseases. As per the British In-Vitro Diagnostic Association, in-vitro diagnostic tests can influence nearly 70% of medical decisions. This factor will have a positive impact on the demand for these devices.

The COVID-19 pandemic accelerated the market’s growth as medical professionals used several in-vitro diagnostic devices to diagnose the COVID-19 virus in patients. The demand for molecular diagnostics increased during this period as several market players were focused on launching advanced testing kits.

F. Hoffmann-La Roche Ltd. Introduced a Smart qPCR system to Fulfill Clinical Requirements in Molecular Diagnostics

F. Hoffmann-La Roche Ltd. announced the launch of a cutting-edge qPCR system that will help the company cater to the clinical requirements of molecular diagnostics. The newly launched system is also expected to help healthcare professionals address health challenges among the patient population.

Growing Cases of Chronic Diseases to Fuel Product Demand

The incidence of chronic diseases, such as diabetes, cardiovascular ailments, and cancer, is on the rise due to a wide range of factors. This factor has boosted the adoption of in-vitro diagnostics (IVD) products as they play a key role in diagnosing life-threatening diseases in their early stages. This helps doctors create an effective treatment plan.

However, the reimbursement scenario surrounding in-vitro diagnostics is quite unfavorable, which can hinder the market’s growth.

Key Market Players to Focus on R&D Activities to Launch Novel Products

Some of the top companies driving the global in-vitro diagnostics (IVD) market growth are increasing their investments in a wide range of research and development activities to launch cutting-edge diagnostic devices. They are also implementing various business growth strategies, such as mergers, partnerships, and collaborations, to expand their current product range and maintain their dominance in the market.

Notable Industry Development

• December 2023 – Thermo Fisher Scientific Inc. announced that it had inked a distribution deal with AESKU GROUP GmbH, a provider of smart diagnostic solutions. This deal was expected to help Thermo Fisher Scientific promote its IFA testing kits and instruments in the U.S.

List of the Companies Profiled in the Report

• F. Hoffmann-La Roche Ltd. (Switzerland)


• Abbott (U.S.)


• Thermo Fisher Scientific Inc.  (U.S.)


• Sysmex Corporation (Japan)


• Siemens Healthineers AG (Germany)


• BD (U.S.)


• Seegene Inc. (Republic of Korea)


• DiaSorin S.p.A. (Italy)


• Quest Diagnostics Incorporated (U.S.)


• Bio-Rad Laboratories, Inc. (U.S.)

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-ivd-market-101443

Further Report Findings

• North America dominated the global in-vitro diagnostics (IVD) market share in 2024 as the region has a robust healthcare infrastructure and a vast presence of leading manufacturers of in-vitro diagnostic products.


• Asia Pacific is predicted to record the fastest CAGR in the coming years owing to factors, such as increasing implementation of reimbursement policies, rising number of product approvals, and growing prevalence of chronic diseases.


• Based on application, the infectious disease segment dominated the market in 2024 due to the rising incidence of these ailments among patients across the globe.

Table of Segmentation